Insider Transactions in Q1 2021 at Syneos Health, Inc. (SYNH)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
Michelle Keefe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,000
-4.11%
|
$156,000
$78.0 P/Share
|
|
Mar 29
2021
|
Linda S Harty Director |
SELL
Open market or private sale
|
Direct |
7,310
-51.35%
|
$555,560
$76.49 P/Share
|
|
Mar 29
2021
|
Jonathan Olefson General Counsel & Corp Secty |
SELL
Open market or private sale
|
Direct |
4,000
-13.93%
|
$308,000
$77.0 P/Share
|
|
Mar 15
2021
|
Donna Hildebrand Kralowetz EVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,348
+15.57%
|
-
|
|
Mar 03
2021
|
Thomas H. Lee Advisors, LLC |
SELL
Open market or private sale
|
Direct |
1,870
-16.02%
|
$138,380
$74.17 P/Share
|
|
Mar 03
2021
|
Thomas H. Lee Advisors, LLC |
SELL
Open market or private sale
|
Indirect |
7,990,038
-15.52%
|
$591,262,812
$74.17 P/Share
|
|
Mar 03
2021
|
Advent International Corp |
SELL
Open market or private sale
|
Indirect |
27,924,276
-15.5%
|
$2,066,396,424
$74.17 P/Share
|
|
Mar 03
2021
|
Tom Allen |
SELL
Open market or private sale
|
Indirect |
4,654,046
-15.5%
|
$344,399,404
$74.17 P/Share
|
|
Mar 03
2021
|
John L. Maldonado |
SELL
Open market or private sale
|
Indirect |
4,654,046
-15.5%
|
$344,399,404
$74.17 P/Share
|
|
Mar 03
2021
|
Donna Hildebrand Kralowetz EVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
248
-4.0%
|
$18,352
$74.64 P/Share
|
|
Mar 02
2021
|
Jonathan Olefson General Counsel & Corp Secty |
BUY
Grant, award, or other acquisition
|
Direct |
1,833
+3.12%
|
-
|
|
Mar 02
2021
|
Paul Colvin Pres., Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
2,677
+4.22%
|
-
|
|
Mar 02
2021
|
Michelle Keefe Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,398
-6.53%
|
$254,850
$75.5 P/Share
|
|
Mar 02
2021
|
Michelle Keefe Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,755
+2.61%
|
-
|
|
Mar 02
2021
|
Jason M. Meggs Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,278
-3.3%
|
$170,850
$75.5 P/Share
|
|
Mar 02
2021
|
Jason M. Meggs Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,258
+2.33%
|
-
|
|
Mar 02
2021
|
Alistair Macdonald Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
31,814
-7.2%
|
$2,386,050
$75.5 P/Share
|
|
Mar 02
2021
|
Alistair Macdonald Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,429
+13.59%
|
-
|
|
Mar 02
2021
|
Alistair Macdonald Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,301
+2.88%
|
-
|
|
Feb 16
2021
|
Michelle Keefe Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,880
-5.53%
|
$224,640
$78.59 P/Share
|
|
Feb 16
2021
|
Donna Hildebrand Kralowetz EVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
362
-5.73%
|
$29,322
$81.0 P/Share
|
|
Feb 16
2021
|
Alistair Macdonald Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,450
-5.93%
|
$971,100
$78.59 P/Share
|
|
Feb 16
2021
|
Jason M. Meggs Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,475
-5.02%
|
$271,050
$78.59 P/Share
|
|
Feb 02
2021
|
Alistair Macdonald Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
278
-0.13%
|
$21,406
$77.11 P/Share
|
|
Feb 01
2021
|
Jonathan Olefson General Counsel & Corp Secty |
SELL
Bona fide gift
|
Direct |
750
-2.76%
|
-
|
|
Feb 01
2021
|
Paul Colvin Pres., Clinical Solutions |
SELL
Open market or private sale
|
Direct |
8,486
-23.08%
|
$627,964
$74.82 P/Share
|
|
Feb 01
2021
|
Alistair Macdonald Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
64,219
-12.16%
|
$4,816,425
$75.5 P/Share
|
|
Jan 25
2021
|
Michelle Keefe Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,000
-7.14%
|
$300,000
$75.68 P/Share
|
|
Jan 25
2021
|
Jonathan Olefson General Counsel & Corp Secty |
SELL
Open market or private sale
|
Direct |
5,336
-16.39%
|
$400,200
$75.68 P/Share
|
|
Jan 17
2021
|
Robert Parks EVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
405
-3.58%
|
$31,185
$77.13 P/Share
|
|
Jan 15
2021
|
Paul Colvin Pres., Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
11,463
+23.77%
|
-
|
|
Jan 15
2021
|
Paul Colvin Pres., Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
1,768
-6.53%
|
$132,600
$75.42 P/Share
|
|
Jan 15
2021
|
Michelle Keefe Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,463
+16.98%
|
-
|
|
Jan 15
2021
|
Michelle Keefe Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,720
-3.71%
|
$129,000
$75.42 P/Share
|
|
Jan 15
2021
|
Alistair Macdonald Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,148
+14.66%
|
-
|
|
Jan 15
2021
|
Alistair Macdonald Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,641
-3.25%
|
$573,075
$75.42 P/Share
|
|
Jan 15
2021
|
Jason M. Meggs Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,344
+16.17%
|
-
|
|
Jan 15
2021
|
Jason M. Meggs Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,367
-2.39%
|
$102,525
$75.42 P/Share
|
|
Jan 15
2021
|
Jonathan Olefson General Counsel & Corp Secty |
BUY
Grant, award, or other acquisition
|
Direct |
8,492
+20.69%
|
-
|
|
Jan 15
2021
|
Jonathan Olefson General Counsel & Corp Secty |
SELL
Payment of exercise price or tax liability
|
Direct |
1,043
-4.16%
|
$78,225
$75.42 P/Share
|
|
Jan 08
2021
|
Jonathan Olefson General Counsel & Corp Secty |
SELL
Payment of exercise price or tax liability
|
Direct |
1,625
-6.08%
|
$118,625
$73.59 P/Share
|
|
Jan 08
2021
|
Robert Parks EVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
679
-5.66%
|
$49,567
$73.59 P/Share
|
|
Jan 08
2021
|
Paul Colvin Pres., Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
2,031
-6.98%
|
$148,263
$73.59 P/Share
|
|
Jan 08
2021
|
Michelle Keefe Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,103
-4.34%
|
$153,519
$73.59 P/Share
|
|
Jan 08
2021
|
Alistair Macdonald Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,154
-4.14%
|
$741,242
$73.59 P/Share
|
|
Jan 08
2021
|
Jason M. Meggs Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,732
-2.94%
|
$126,436
$73.59 P/Share
|
|
Jan 06
2021
|
Jason M. Meggs Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,552
-8.61%
|
$399,744
$72.0 P/Share
|
|
Jan 02
2021
|
Paul Colvin Pres., Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
249
-0.85%
|
$16,683
$67.36 P/Share
|